India’s pharmaceutical industry is entering a new phase in which its established manufacturing strength is expected to support a broader ambition: becoming a global centre for pharmaceutical research, innovation and advanced healthcare technologies.
Speaking about the sector’s future, Dr M. Srinivas, Member (Health), NITI Aayog, underlined the importance of stronger collaboration between academia and industry. The emphasis is shifting from producing medicines at scale to developing new therapies, advanced biological products and innovative healthcare solutions.
From Manufacturing Scale to Innovation Capability
India has built a strong position in the global pharmaceutical market through its capabilities in generic medicines, vaccines, active pharmaceutical ingredients and contract manufacturing.
According to government data, India ranks among the world’s leading pharmaceutical producers by volume, with more than 3,000 pharmaceutical companies and approximately 10,500 manufacturing units. The sector has also developed a substantial export base serving regulated markets across the world.
However, the next stage of growth will require the industry to expand beyond volume-driven manufacturing. Greater emphasis is being placed on:
- New drug discovery
- Innovative formulations
- Biologics and biosimilars
- Advanced therapies
- Cell and gene therapy
- mRNA-based technologies
- Antibody-drug conjugates
- Multispecific medicines
- Clinical research and translational science
- Artificial intelligence-led drug development
This transition could help Indian companies capture a larger share of the value generated across the pharmaceutical innovation chain.
Stronger Academia–Industry Collaboration
A closer relationship between universities, research institutions, start-ups and pharmaceutical companies is expected to be an important factor in India’s innovation ambitions.
Academic institutions can contribute scientific research, talent and early-stage discoveries, while pharmaceutical companies can provide development infrastructure, regulatory expertise, manufacturing capabilities and access to global markets.
Such partnerships can help reduce the gap between laboratory research and commercially viable healthcare products.
The industry’s future innovation ecosystem is likely to depend on the development of shared research infrastructure, technology-transfer mechanisms, advanced laboratories and funding models that support projects over longer development cycles.
Government Support for Research and Development
The government has introduced initiatives intended to encourage research, innovation and high-value manufacturing in strategic sectors, including pharmaceuticals and biotechnology.
The Research, Development and Innovation framework and the proposed Biopharma Shakti Mission are expected to support the development of advanced pharmaceutical capabilities, strengthen domestic research infrastructure and encourage industry participation in innovation-led projects.
Policy support is particularly important because innovative drug development involves substantial expenditure, lengthy clinical-development timelines and considerable regulatory uncertainty.
A stronger R&D ecosystem could help Indian companies move from supplying products developed elsewhere to participating more actively in the discovery and development of original medicines.
Opportunities in Biopharmaceuticals and Advanced Therapies
The global pharmaceutical industry is witnessing rapid development in biological medicines and advanced treatment platforms.
For Indian companies, potential growth areas include:
Biologics and Biosimilars
India already has experience in biotechnology and biosimilar manufacturing. Continued investment in analytical capabilities, process development and regulatory compliance could strengthen the country’s position in global biologics markets.
Cell and Gene Therapies
Cell and gene therapies require specialised manufacturing systems, advanced quality controls and highly skilled scientific teams. Developing these capabilities could create opportunities for Indian biotechnology companies and contract development and manufacturing organisations.
mRNA and Next-Generation Platforms
mRNA-based medicines and vaccines, multispecific therapies and other emerging platforms are creating new demand for specialised research, formulation and manufacturing infrastructure.
Antibody-Drug Conjugates
Antibody-drug conjugates combine biological targeting with drug-delivery technologies. Their development requires expertise in biologics, chemistry, conjugation and high-quality manufacturing processes.
AI-Enabled Drug Discovery
Artificial intelligence and advanced analytics are increasingly being used to identify drug candidates, study biological targets, improve clinical-trial design and optimise manufacturing processes.
India’s large scientific and technology talent pool could support the expansion of these capabilities, provided research infrastructure and industry partnerships continue to improve.
Role of Start-Ups and CRDMOs
Pharmaceutical start-ups are expected to play an important role in India’s transition towards innovation-led growth.
Early-stage companies can focus on specialised scientific problems, novel therapeutic platforms and niche healthcare applications. However, many start-ups face challenges related to funding, clinical development, regulatory approvals and manufacturing scale-up.
Collaboration with contract research, development and manufacturing organisations, commonly known as CRDMOs, can help start-ups access technical infrastructure and reduce the cost of developing new products.
Such partnerships can support:
- Preclinical research
- Analytical development
- Process development
- Clinical-sample manufacturing
- Scale-up activities
- Regulatory documentation
- Commercial production
This model can help connect scientific discoveries with industrial-scale manufacturing.
Investment, Skills and Infrastructure Requirements
Moving towards global innovation leadership will require sustained investment across several areas.
Research Infrastructure
India needs more advanced laboratories, shared research facilities, high-containment infrastructure, bioprocessing facilities and technology platforms.
Scientific Talent
The development of innovative medicines requires scientists, engineers, clinical researchers, regulatory specialists, data scientists and specialised manufacturing professionals.
Retaining skilled researchers in India and attracting experienced Indian scientists from overseas could strengthen the domestic innovation ecosystem.
Intellectual Property Protection
Strong and predictable intellectual property systems are important for encouraging private investment in original drug discovery and technology development.
Clinical Research
Efficient, transparent and scientifically robust clinical-trial processes will be essential for translating research into approved medicines.
Regulatory Capability
The industry will require regulatory systems capable of supporting emerging technologies while maintaining patient safety, product quality and scientific standards.
Bengaluru and India’s Broader Life-Science Ecosystem
India’s innovation transition is also creating opportunities for established life-science clusters such as Bengaluru, Hyderabad, Pune, Ahmedabad, Mumbai and the National Capital Region.
These locations bring together pharmaceutical companies, biotechnology firms, universities, hospitals, research institutions, engineering companies and technology providers.
Bengaluru, in particular, has a strong base in biotechnology, engineering, digital technologies and research services. The convergence of these capabilities could support innovation in drug discovery, bioprocessing, digital health and advanced manufacturing.
Employment and Industrial Opportunities
The transition towards innovation-led pharmaceuticals could create demand for specialised employment in:
- Pharmaceutical research and development
- Biotechnology
- Clinical research
- Bioinformatics
- Data science
- Regulatory affairs
- Quality assurance
- Advanced manufacturing
- Process engineering
- Laboratory services
- Pharmaceutical equipment
- Cold-chain and specialised logistics
However, the ANI report does not provide a specific investment figure or direct employment target associated with the sector-wide innovation transition. Therefore, no project-specific investment or job number should be attributed to this development.
Key Takeaways
- India’s pharmaceutical industry is seeking to move beyond manufacturing scale towards innovation-led growth.
- Stronger academia–industry collaboration is expected to support drug discovery and advanced healthcare technologies.
- Government initiatives are focusing on research, development and high-value pharmaceutical capabilities.
- Biologics, biosimilars, cell and gene therapies, mRNA, antibody-drug conjugates and AI-enabled drug discovery are emerging opportunity areas.
- Start-ups and CRDMOs can help accelerate the movement from laboratory research to commercial production.
- Research infrastructure, skilled talent, intellectual property protection and efficient clinical-trial systems will be important enablers.
- No specific sector-wide investment or employment figure was disclosed in the report.
The Bigger Picture
India’s pharmaceutical success has traditionally been associated with affordable medicines, generic manufacturing, vaccines and global supply-chain capabilities. The next phase will require the country to strengthen its position in original research, advanced therapeutics and technology-intensive pharmaceutical production.
A successful transition will depend on sustained investment, stronger scientific partnerships, improved infrastructure and the ability to convert research outcomes into commercially viable products.
If these capabilities continue to develop, India’s pharmaceutical sector could increasingly participate in the complete value chain—from scientific discovery and clinical development to advanced manufacturing and global commercialisation.
